Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer-Reference-Cited by-同舟云学术

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Published:2018-10 Issue:10 Volume:29 Page:2068-2075
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kron A.^ORCID,Alidousty C.,Scheffler M.^ORCID,Merkelbach-Bruse S.,Seidel D.,Riedel R.,Ihle M.A.,Michels S.,Nogova L.,Fassunke J.,Heydt C.,Kron F.,Ueckeroth F.,Serke M.,Krüger S.,Grohe C.,Koschel D.,Benedikter J.,Kaminsky B.,Schaaf B.,Braess J.,Sebastian M.,Kambartel K -O,Thomas R.,Zander T.,Schultheis A.M.,Büttner R.,Wolf J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/10/2068/26468265/mdy333.pdf

Reference37 articles.

1. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset;Inamura;Mod Pathol,2009

2. Hunting ALK to feed targeted cancer therapy;Wellstein;Nat Med,2011

3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

5. A genomics-based classification of human lung tumors;Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM);Sci Transl Med,2013

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17);ESMO Open;2024-09

2. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

3. Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations;Cancer Reports;2024-08

4. Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study;Cancer Communications;2024-07-17

5. Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib;Frontiers in Oncology;2024-07-08